^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

drozitumab (RG7425)

i
Other names: RG7425, PRO95780
Associations
Company:
Roche
Drug class:
TRAIL R2 agonist
Associations
18d
Combination of multivalent DR5 receptor clustering agonists and histone deacetylase inhibitors for treatment of colon cancer. (PubMed, J Control Release)
In TRAIL-sensitive colon cancer cells (COLO205, HCT-116), P-cDR5 showed efficacy comparable to anti-DR5 mAb Drozitumab (DRO), but P-cDR5 outperformed DRO in TRAIL-resistant cells (HT-29), highlighting the importance of efficient receptor clustering...Combining P-cDR5 with valproic acid, a histone deacetylase inhibitor, resulted in further enhancement of apoptosis inducing efficacy, along with destabilizing mitochondrial membranes and increased sensitivity of TRAIL-resistant cells. These findings suggest that attaching multiple cDR5 peptides to a flexible water-soluble polymer carrier not only overcomes the limitations of previous designs but also offers a promising avenue for treating resistant cancers, pointing toward the need for further preclinical exploration and validation of this innovative strategy.
Journal • Epigenetic controller
|
TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF10B (TNF Receptor Superfamily Member 10b)
|
drozitumab (RG7425)
3years
The RNA-binding protein La/SSB associates with radiation-induced DNA double-strand breaks in lung cancer cell lines. (PubMed, Cancer Rep (Hoboken))
The co-localisation of La/SSB with radiation-induced DNA breaks suggests a role of La/SSB in DNA repair, however further experimentation is required to validate this.
Preclinical • Journal
|
RAD51 (RAD51 Homolog A)
|
drozitumab (RG7425)